Stock Analysis
A Look At The Intrinsic Value Of Imeik Technology Development Co.,Ltd. (SZSE:300896)
Key Insights
- Imeik Technology DevelopmentLtd's estimated fair value is CN¥235 based on 2 Stage Free Cash Flow to Equity
- With CN¥202 share price, Imeik Technology DevelopmentLtd appears to be trading close to its estimated fair value
- The CN¥267 analyst price target for 300896 is 14% more than our estimate of fair value
How far off is Imeik Technology Development Co.,Ltd. (SZSE:300896) from its intrinsic value? Using the most recent financial data, we'll take a look at whether the stock is fairly priced by taking the expected future cash flows and discounting them to their present value. Our analysis will employ the Discounted Cash Flow (DCF) model. There's really not all that much to it, even though it might appear quite complex.
Companies can be valued in a lot of ways, so we would point out that a DCF is not perfect for every situation. For those who are keen learners of equity analysis, the Simply Wall St analysis model here may be something of interest to you.
Check out our latest analysis for Imeik Technology DevelopmentLtd
Crunching The Numbers
We're using the 2-stage growth model, which simply means we take in account two stages of company's growth. In the initial period the company may have a higher growth rate and the second stage is usually assumed to have a stable growth rate. In the first stage we need to estimate the cash flows to the business over the next ten years. Where possible we use analyst estimates, but when these aren't available we extrapolate the previous free cash flow (FCF) from the last estimate or reported value. We assume companies with shrinking free cash flow will slow their rate of shrinkage, and that companies with growing free cash flow will see their growth rate slow, over this period. We do this to reflect that growth tends to slow more in the early years than it does in later years.
A DCF is all about the idea that a dollar in the future is less valuable than a dollar today, so we need to discount the sum of these future cash flows to arrive at a present value estimate:
10-year free cash flow (FCF) estimate
2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 | |
Levered FCF (CN¥, Millions) | CN¥2.27b | CN¥2.61b | CN¥2.87b | CN¥3.09b | CN¥3.28b | CN¥3.45b | CN¥3.60b | CN¥3.75b | CN¥3.88b | CN¥4.01b |
Growth Rate Estimate Source | Analyst x2 | Analyst x2 | Est @ 9.79% | Est @ 7.69% | Est @ 6.22% | Est @ 5.20% | Est @ 4.48% | Est @ 3.97% | Est @ 3.62% | Est @ 3.38% |
Present Value (CN¥, Millions) Discounted @ 7.1% | CN¥2.1k | CN¥2.3k | CN¥2.3k | CN¥2.3k | CN¥2.3k | CN¥2.3k | CN¥2.2k | CN¥2.2k | CN¥2.1k | CN¥2.0k |
("Est" = FCF growth rate estimated by Simply Wall St)
Present Value of 10-year Cash Flow (PVCF) = CN¥22b
We now need to calculate the Terminal Value, which accounts for all the future cash flows after this ten year period. The Gordon Growth formula is used to calculate Terminal Value at a future annual growth rate equal to the 5-year average of the 10-year government bond yield of 2.8%. We discount the terminal cash flows to today's value at a cost of equity of 7.1%.
Terminal Value (TV)= FCF2034 × (1 + g) ÷ (r – g) = CN¥4.0b× (1 + 2.8%) ÷ (7.1%– 2.8%) = CN¥96b
Present Value of Terminal Value (PVTV)= TV / (1 + r)10= CN¥96b÷ ( 1 + 7.1%)10= CN¥48b
The total value, or equity value, is then the sum of the present value of the future cash flows, which in this case is CN¥71b. The last step is to then divide the equity value by the number of shares outstanding. Relative to the current share price of CN¥202, the company appears about fair value at a 14% discount to where the stock price trades currently. Valuations are imprecise instruments though, rather like a telescope - move a few degrees and end up in a different galaxy. Do keep this in mind.
Important Assumptions
The calculation above is very dependent on two assumptions. The first is the discount rate and the other is the cash flows. Part of investing is coming up with your own evaluation of a company's future performance, so try the calculation yourself and check your own assumptions. The DCF also does not consider the possible cyclicality of an industry, or a company's future capital requirements, so it does not give a full picture of a company's potential performance. Given that we are looking at Imeik Technology DevelopmentLtd as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighted average cost of capital, WACC) which accounts for debt. In this calculation we've used 7.1%, which is based on a levered beta of 0.862. Beta is a measure of a stock's volatility, compared to the market as a whole. We get our beta from the industry average beta of globally comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business.
SWOT Analysis for Imeik Technology DevelopmentLtd
- Earnings growth over the past year exceeded the industry.
- Currently debt free.
- Earnings growth over the past year is below its 5-year average.
- Annual revenue is forecast to grow faster than the Chinese market.
- Good value based on P/E ratio and estimated fair value.
- Annual earnings are forecast to grow slower than the Chinese market.
Moving On:
Valuation is only one side of the coin in terms of building your investment thesis, and it is only one of many factors that you need to assess for a company. The DCF model is not a perfect stock valuation tool. Preferably you'd apply different cases and assumptions and see how they would impact the company's valuation. If a company grows at a different rate, or if its cost of equity or risk free rate changes sharply, the output can look very different. For Imeik Technology DevelopmentLtd, we've put together three relevant elements you should further examine:
- Risks: For example, we've discovered 1 warning sign for Imeik Technology DevelopmentLtd that you should be aware of before investing here.
- Future Earnings: How does 300896's growth rate compare to its peers and the wider market? Dig deeper into the analyst consensus number for the upcoming years by interacting with our free analyst growth expectation chart.
- Other High Quality Alternatives: Do you like a good all-rounder? Explore our interactive list of high quality stocks to get an idea of what else is out there you may be missing!
PS. The Simply Wall St app conducts a discounted cash flow valuation for every stock on the SZSE every day. If you want to find the calculation for other stocks just search here.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About SZSE:300896
Imeik Technology DevelopmentLtd
Engages in the research and development, production, and transformation of biomedical soft tissue repair materials in China.